On July 21, 2026, the Drug Controller General of India (DCGI) granted market authorization to QDENGA, a dengue vaccine developed by Takeda Biopharmaceuticals India, for use in individuals aged 4 to 60 years. This marks the first dengue vaccine approved in India.
QDENGA is a live-attenuated tetravalent vaccine that targets all four serotypes of the dengue virus. Clinical trials have shown it to be effective in reducing the incidence of dengue fever and severe dengue, with a favorable safety profile.
Dengue is a major public health concern in India, with hundreds of thousands of cases reported annually. The approval of QDENGA is expected to help control the spread of the disease, particularly in endemic regions.
The vaccine will be available in the private market initially, with plans for inclusion in the national immunization program pending further evaluation. Takeda has committed to ensuring affordable pricing and adequate supply.
